甲地孕酮对贲门癌FolFox方案化疗并同步放疗患者生活质量的影响

The improvement of the quality of life by megestrol acetate in patients with cardia cancer by FOLFOX regimen combined with radiotherapy

目的:观察甲地孕酮(MA)FolFox方案化疗并同步放疗对贲门癌患者生活质量的影响。方法:53例贲门癌患者随机分成实验组和对照组,所有患者均给予FolFox方案化疗并同步放疗(DT:60Gy/30F),其中实验组同时给予MA口服,观察患者治疗前后KPS评分、食欲、体重、睡眠变化情况及不良反应。结果:实验组治疗后KPS评分升高0.7,而对照组降低了10.4,两组间KPS评分在治疗后比较有显著性差异(P<0.05);实验组治疗后食欲增加者占74.1%(20/27),对照组食欲增加者占7.7%(2/26),两组间比较有显著性差异(P<0.05);实验组治疗后体重增加者占51.9%(14/27),对照组体重增加者占11.5%(3/26),两组间比较有显著性差异(P<0.05);实验组治疗后睡眠好者占48.1%(13/27),对照组睡眠好者占26.9%(7/26),两组间比较有显著性差异(P<0.05)。实验组未见甲地孕酮所致的严重不良反应。结论:甲地孕酮能明显提高FolFox方案化疗并同步放疗贲门癌患者的生活质量。

Objective：To investigate the effects of megestrol acetate（MA） to improve the quality of life in patients with cardia cancer treated by FOLFOX regimen combined with radiotherapy.Methods：53 cases with cardia cancer were randomly divided into two groups：27 cases in trial group（MA＋FOLFOX＋Radiotherapy） and 26 cases in control group（FOLFOX＋Radiotherapy）.the change of KPS,appetite,body weight,sleep and toxicity in each group after treatment were observed.Results：In KPS there was no significant difference between two groups.Before chemotherapy combined with radiotherapy,while significant difference were shown with 0.7 rising in trial group and-10.4 increased in control group after the treatment.Significant statistical difference（P0.05） was shown with 13 more in the former than the latter in KPS after treatment.Obvious improvements（P0.05） were also shown in the member of appetite improved in 74.1%（20/27）,body weight increased in 51.9%（14/27） and sleep better in 48.1%（13/27） in trial group,compared with 7.7%（2/26）,11.5%（3/26）,and 26.9%（7/26） in control group after the treatment in statistics.No obviously serious side-effects from megestrol acetate（MA） were discovered in trial group after treatment.Conclusion：Megestrol acetate can significantly improve the quality of life in patients with small cell lung cancer treated by FOLFOX regimen.